Related Experiment Videos
[Cancer curable by chemotherapy: malignant lymphoma]
1Dept. of Clinical Oncology, Japanese Foundation for Cancer Research.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|April 1, 1989
Summary
Chemotherapy regimens for malignant lymphoma have evolved, with combination, alternating, and hybrid approaches showing improved outcomes. However, Japan
Area of Science:
- Oncology
- Hematology
- Clinical Pharmacology
Context:
- Chemotherapy is a cornerstone in treating malignant lymphoma.
- Treatment strategies have evolved towards combination, alternating, and hybrid regimens.
- Long-term follow-up data are crucial for evaluating treatment efficacy.
Purpose:
- To summarize trends and long-term outcomes of chemotherapy regimens for Hodgkin's disease and non-Hodgkin's lymphoma (NHL).
- To compare the efficacy of different chemotherapy generations for NHL.
- To assess the effectiveness of novel regimens in Japanese patient cohorts.
Summary:
- Hodgkin's disease shows high complete remission (CR) and relapse-free survival (RFS) rates with MOPP and MOPP-ABV regimens.
- NHL treatment has progressed through three generations (CHOP, Pro-MACE/MOPP, MACOP-B), with significant improvements in CR and long-term survival.
- MACOP-B regimen demonstrated an 84% CR and 69% RFS at 6.5 years in large-cell lymphoma.
- Novel regimens in Japanese studies showed a 56% CR rate, with lower overall curability rates for NHL compared to international standards.
Impact:
- Highlights the advancements in lymphoma chemotherapy, particularly for NHL.
- Identifies MACOP-B as a highly effective regimen for large-cell lymphoma.
- Indicates a need for improved chemotherapy strategies to enhance NHL curability in Japan.